A unit of Johnson & Johnson said Monday that a federal jury has ordered Abbott Laboratories to pay $1.67 billion in a patent infringement suit over the companies’ rheumatoid arthritis drugs. Abbott’s best-selling drug, Humira, competes with the drug Remicade,…

Email this Article
Add to del.icio.us
Add to digg
Add to Facebook



Sponsored Topics:
Johnson & Johnson – Abbott Laboratories – Rheumatoid arthritis – Adalimumab – Infliximab

More here:
J&J unit wins $1.67 billion verdict vs Abbott Labs